ArticleBMC systems biology2018
Escherichia coli B2 strains prevalent in inflammatory bowel disease patients have distinct metabolic capabilities that enable colonization of intestinal mucosa.
Article in BMC systems biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Deciphering the Implications ofPathogens (Basel, Switzerland) · 2026Review
- Identification of specific metabolic capacities associated with major extraintestinal pathogenicJournal of bacteriology · 2026Article
- Structure of theMicrobiology spectrum · 2026Article
- Use of genome-scale metabolic reconstructions of avian pathogenicMicrobial genomics · 2025Article
- Improved detection of microbiome-disease associations via population structure-aware generalized linear mixed effects models (microSLAM).PLoS computational biology · 2025Article
- The role of bacterial metabolism in human gut colonization.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Review
- Article
- Genome characterization of a multi-drug resistantFrontiers in microbiology · 2024Article
- Beneficial Effect of Faecal Microbiota Transplantation on Mild, Moderate and Severe Dextran Sodium Sulphate-Induced Ulcerative Colitis in a Pseudo Germ-Free Animal Model.Biomedicines · 2023Article
- How reliable are Chinese hamster ovary (CHO) cell genome-scale metabolic models?Biotechnology and bioengineering · 2023Article
- New Insights on Metabolic Features ofInternational journal of molecular sciences · 2023Article
- Article
- Evidence for Widespread Class II Microcins inApplied and environmental microbiology · 2022Article
- Role of adherent invasiveWorld journal of clinical cases · 2022Review
- Transmissibility and Persistence of the Plasmid-Borne Mobile Colistin Resistance Gene,Antibiotics (Basel, Switzerland) · 2022Article
- A curated collection ofGenome research · 2022Article
- Phylogrouping and characterization ofFrontiers in medicine · 2022Article
- High prevalence of multiple antibiotic resistance in clinical E. coli isolates from Bangladesh and prediction of molecular resistance determinants using WGS of an XDR isolate.Scientific reports · 2021Article
- Path to improving the life cycle and quality of genome-scale models of metabolism.Cell systems · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundEscherichia coli is considered a leading bacterial trigger of inflammatory bowel disease (IBD). E. coli isolates from IBD patients primarily belong to phylogroup B2. Previous studies have focused on broad comparative genomic analysis of E. coli B2 isolates, and identified virulence factors that allow B2 strains to reside within human intestinal mucosa. Metabolic capabilities of E. coli strains have been shown to be related to their colonization site, but remain unexplored in IBD-associated strains.
resultsIn this study, we utilized pan-genome analysis and genome-scale models (GEMs) of metabolism to study metabolic capabilities of IBD-associated E. coli B2 strains. The study yielded three results: i) Pan-genome analysis of 110 E. coli strains (including 53 isolates from IBD studies) revealed discriminating metabolic genes between B2 strains and other strains; ii) Both comparative genomic analysis and GEMs suggested that B2 strains have an advantage in degrading and utilizing sugars derived from mucus glycan, and iii) GEMs revealed distinct metabolic features in B2 strains that potentially allow them to utilize energy more efficiently. For example, B2 strains lack the enzymes to degrade amadori products, but instead rely on neighboring bacteria to convert these substrates into a more readily usable and potentially less sought after product.
conclusionsTaken together, these results suggest that the metabolic capabilities of B2 strains vary significantly from those of other strains, enabling B2 strains to colonize intestinal mucosa.The results from this study motivate a broad experimental assessment of the nutritional effects on E. coli B2 pathophysiology in IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.